-
2025-523259-72-00
5
Hidradenitis Suppurativa (HS)
-
2025-523285-25-00
5
Relapsed or Refractory Multiple Myeloma
-
2025-523399-22-00
7
Melanoma
-
2025-523443-35-00
5
Persistent Corneal Epithelial Defect (PCED)
-
2025-523525-17-00
9
Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523869-22-00
5
advanced or metastatic extrapulmonary neuroendocrine carcinoma
-
2025-523971-46-00
7
Diffuse cutaneous systemic sclerosis (dcSSc)
Difficult to treat rheuma
-
2025-524435-39-00
4
Localized Scleroderma
-
2025-524468-40-00
3
chronic Graft-versus-Host-Disease (cGvHD)
-
2025-525068-13-00
4
Chronic Kidney Disease
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-522387-32-00
5
2026-04-10
Uveal Melanoma
-
2025-523342-27-00
4
2026-04-10
Alopecia areata
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-